174 related articles for article (PubMed ID: 32033205)
21. Activation of extracellular signal-regulated kinase and c-Jun-NH(2)-terminal kinase but not p38 mitogen-activated protein kinases is required for RRR-alpha-tocopheryl succinate-induced apoptosis of human breast cancer cells.
Yu W; Liao QY; Hantash FM; Sanders BG; Kline K
Cancer Res; 2001 Sep; 61(17):6569-76. PubMed ID: 11522656
[TBL] [Abstract][Full Text] [Related]
22. Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6.
Hsiao YC; Yeh MH; Chen YJ; Liu JF; Tang CH; Huang WC
Oncotarget; 2015 Nov; 6(35):37965-78. PubMed ID: 26513016
[TBL] [Abstract][Full Text] [Related]
23. Phytochemicals inhibit migration of triple negative breast cancer cells by targeting kinase signaling.
Shahi Thakuri P; Gupta M; Singh S; Joshi R; Glasgow E; Lekan A; Agarwal S; Luker GD; Tavana H
BMC Cancer; 2020 Jan; 20(1):4. PubMed ID: 31898540
[TBL] [Abstract][Full Text] [Related]
24. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
Wang S; Yao Y; Yao M; Fu P; Wang W
Biochem Biophys Res Commun; 2018 Sep; 503(3):1605-1609. PubMed ID: 30072097
[TBL] [Abstract][Full Text] [Related]
25. AHNAK suppresses tumour proliferation and invasion by targeting multiple pathways in triple-negative breast cancer.
Chen B; Wang J; Dai D; Zhou Q; Guo X; Tian Z; Huang X; Yang L; Tang H; Xie X
J Exp Clin Cancer Res; 2017 May; 36(1):65. PubMed ID: 28494797
[TBL] [Abstract][Full Text] [Related]
26. Ginsenoside Rk1 induces cell cycle arrest and apoptosis in MDA-MB-231 triple negative breast cancer cells.
Hong Y; Fan D
Toxicology; 2019 Apr; 418():22-31. PubMed ID: 30797898
[TBL] [Abstract][Full Text] [Related]
27. Sulforaphene inhibits triple negative breast cancer through activating tumor suppressor Egr1.
Yang M; Teng W; Qu Y; Wang H; Yuan Q
Breast Cancer Res Treat; 2016 Jul; 158(2):277-86. PubMed ID: 27377973
[TBL] [Abstract][Full Text] [Related]
28. All-trans-retinoic acid activates the pro-invasive Src-YAP-Interleukin 6 axis in triple-negative MDA-MB-231 breast cancer cells while cerivastatin reverses this action.
Mezquita B; Mezquita P; Pau M; Gasa L; Navarro L; Samitier M; Pons M; Mezquita C
Sci Rep; 2018 May; 8(1):7047. PubMed ID: 29728589
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
[TBL] [Abstract][Full Text] [Related]
30. Chetomin induces apoptosis in human triple-negative breast cancer cells by promoting calcium overload and mitochondrial dysfunction.
Dewangan J; Srivastava S; Mishra S; Pandey PK; Divakar A; Rath SK
Biochem Biophys Res Commun; 2018 Jan; 495(2):1915-1921. PubMed ID: 29208466
[TBL] [Abstract][Full Text] [Related]
31. Ziyuglycoside II suppresses the aggressive phenotype of triple negative breast cancer cells through regulating Src/EGFR-dependent ITGB4/FAK signaling.
Wang K; Zou P; Zhu X; Zhang T
Toxicol In Vitro; 2019 Dec; 61():104653. PubMed ID: 31525383
[TBL] [Abstract][Full Text] [Related]
32. Marine natural compound cyclo(L-leucyl-L-prolyl) peptide inhibits migration of triple negative breast cancer cells by disrupting interaction of CD151 and EGFR signaling.
Kgk D; Kumari S; G S; Malla RR
Chem Biol Interact; 2020 Jan; 315():108872. PubMed ID: 31669320
[TBL] [Abstract][Full Text] [Related]
33. Alcohol dehydrogenase-1B represses the proliferation, invasion and migration of breast cancer cells by inactivating the mitogen-activated protein kinase signalling pathway.
Jiang C; Liu R; Wu X
J Physiol Pharmacol; 2023 Oct; 74(5):. PubMed ID: 38085522
[TBL] [Abstract][Full Text] [Related]
34. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
[TBL] [Abstract][Full Text] [Related]
35. Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.
Lee J; Lim B; Pearson T; Choi K; Fuson JA; Bartholomeusz C; Paradiso LJ; Myers T; Tripathy D; Ueno NT
Breast Cancer Res Treat; 2019 Jun; 175(2):339-351. PubMed ID: 30826934
[TBL] [Abstract][Full Text] [Related]
36. Lactate dehydrogenase downregulation mediates the inhibitory effect of diallyl trisulfide on proliferation, metastasis, and invasion in triple-negative breast cancer.
Cheng SY; Yang YC; Ting KL; Wen SY; Viswanadha VP; Huang CY; Kuo WW
Environ Toxicol; 2017 Apr; 32(4):1390-1398. PubMed ID: 27566995
[TBL] [Abstract][Full Text] [Related]
37. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
[TBL] [Abstract][Full Text] [Related]
38. Eriocalyxin B induces apoptosis in human triple negative breast cancer cells via inhibiting STAT3 activation and mitochondrial dysfunction.
Riaz A; Rasul A; Hussain G; Zubair M; Samiullah K; Sarfraz I; Masood M; Jabeen F; Sultana T; Sultana S
Pak J Pharm Sci; 2019 Nov; 32(6(Supplementary)):2843-2848. PubMed ID: 32024623
[TBL] [Abstract][Full Text] [Related]
39. Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity.
Fultang N; Illendula A; Chen B; Wu C; Jonnalagadda S; Baird N; Klase Z; Peethambaran B
PLoS One; 2019; 14(5):e0217789. PubMed ID: 31150511
[TBL] [Abstract][Full Text] [Related]
40. RSK-mediated down-regulation of PDCD4 is required for proliferation, survival, and migration in a model of triple-negative breast cancer.
Cuesta R; Holz MK
Oncotarget; 2016 May; 7(19):27567-83. PubMed ID: 27028868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
